A Phase 2, Open-label, Multi-centre Study to Assess the Efficacy and Safety of Intravitreal THR-317 for the Treatment of Macular Telangiectasia Type 1 (MacTel 1)
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2019
At a glance
- Drugs THR 317 (Primary)
- Indications Retinal telangiectasis
- Focus Therapeutic Use
- Sponsors Oxurion
- 19 Oct 2018 According to an Oxurion media release, initial results from this clinical study are anticipated towards the end of the second half of 2019.
- 21 Sep 2018 New trial record
- 20 Sep 2018 According to an Oxurion media release, first patient has been enrolled.